Clinical Trial: Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816328) titled 'Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks' on Sept. 07.

Brief Summary: The purpose of this open-label study is to assess the efficacy and safety of a novel treatment algorithm for sequencing remibrutinib and omalizumab in the treatment of adult participants with chronic spontaneous urticaria (CSU) who are inadequately controlled by second-generation H1-antihistamines (sgH1-AH).

Study Start Date: Nov. 09

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous Urticaria

Intervention:...